Gapping up
In reaction to strong earnings/guidance:
- SE +8.1%, SE +8.1%, AAP +5.9%, LX +4.2%, GOGL +4%, AMCR +3.9%, CRMT +2.8%, ARCE +2.5%, HD +1%, SFL +0.8%
Other news:
- TLSA +16% (receives patent for methods and use of anti-CD3 monoclonal antibodies for treatment of Crohn's disease)
- VNDA +11.6% (reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 (COVID-19) pneumonia in the ODYSSEY study)
- REDU +7.4% (extends momentum from +48% move during Monday regular session)
- RXT +5.4% (extends momentum from +10% move during Monday regular session)
- MCRB +5.2% (prices 12,075,000 share offering at $21.50/sh)
- KL +3.3% (signs Strategic Alliance Agreement with NEM)
- KRYS +3.1% (FDA has granted Orphan Drug Designation to KB407)
- KNDI +2.4% (extends momentum from +10% move during Monday regular session)
- CHGG +2.2% (convertible notes offering)
- SDGR +1.6% (prices 5.75 mln share offering at $66/sh)
- NEM +1.5% (signs Strategic Alliance Agreement with KL)
- EPC +1.2% (S&P says 'BB' rating affirmed on Cremo acquisition)
- RUN +1.2% (Sunrun and Vivint Solar (VSLR) announce that Coatue US 24 LLC entered into a Stock Purchase Agreement with 313 Acquisition for the purchase of 11,627,907 shares of Vivint Solar common stock in a private transaction)
Analyst comments:
- BBDC +2.2% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- BBY +2% (pgraded to Outperform from Neutral at Wedbush)
- JD +1.5% (added to Conviction Buy List at Goldman)